{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:49:13Z","timestamp":1792727353821,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold>  <jats:italic>Babesia microti<\/jats:italic> is an intraerythrocytic parasite, transmitted naturally to humans by infected ixodid ticks, that causes babesiosis. In recent years, <jats:italic>B. microti<\/jats:italic> has been identified as a growing public health concern that has also emerged as a critical blood safety issue in the absence of appropriate interventions to reduce transmission by blood transfusion. Thus, we evaluated the ability of the Mirasol pathogen reduction technology (PRT; CaridianBCT), which uses riboflavin (RB) and ultraviolet (UV) light, to diminish the presence of <jats:italic>B. microti<\/jats:italic> in apheresis plasma and platelets (PLTs).<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Apheresis plasma and PLT units were spiked with <jats:italic>B. microti<\/jats:italic>\u2010infected hamster blood and subsequently treated using the Mirasol PRT system. Control and experimental samples were collected at different stages during the treatment process and injected into hamsters to detect the presence of viable parasites. Four weeks postinoculation, hamster blood was tested for <jats:italic>B. microti<\/jats:italic> infection by blood smear and real\u2010time polymerase chain reaction analysis.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> None of the blood smears from animals injected with samples from PRT\u2010treated plasma or PLT units were positive by microscopy, while all the non\u2013PRT\u2010treated plasma and PLT units were demonstrably parasitemic. Parasite load reduction in hamsters ranged between 4 and 5 log in all PRT\u2010treated units compared to untreated controls.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> The data indicate that the use of RB and UV light efficiently reduces the presence of viable <jats:italic>B. microti<\/jats:italic> in apheresis plasma and PLT products, thereby reducing the risk of transfusion\u2010transmitted <jats:italic>Babesia<\/jats:italic> potentially associated with these products. Based on this observed \u201cproof of principle,\u201d future studies will determine the efficacy of the Mirasol PRT in whole blood.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2009.02538.x","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T19:39:59Z","timestamp":1261165199000},"page":"1019-1027","source":"Crossref","is-referenced-by-count":54,"title":["Evaluation of the Mirasol platelet reduction technology system against <i>Babesia microti<\/i> in apheresis platelets and plasma"],"prefix":"10.1111","volume":"50","author":[{"given":"Laura","family":"Tonnetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie C.","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond P.","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Leiby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03355.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00777.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00939.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000287318.94088.d7"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2007.12.003"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00736.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.07.002"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01094.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00740.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.6.1019"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.2307\/3283978"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1991.31491213305.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/595010"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02317.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/tmrv.2002.31462"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011063031906"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040440.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1309\/N3DP9MFPNUJD4XJY"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/01913120309916"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01512.x"},{"key":"e_1_2_8_22_2","unstructured":"US Food and Drug Administration.FDA workshop to consider approaches to reduce the risk of transfusion\u2010transmitted babesiosis in the United States. [September 12 2008 Lister Hill Center Auditorium Building 38A National Institute of Health 8800 Rockville Pike Bethesda MD 20894][cited 2009 Jun 23]. Available from: URL:http:\/\/wwww.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/TranscriptsMinutes\/UCM051501.pdf"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.2307\/3277582"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01762.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.88-96.2000"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/593812"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00245.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2009.02538.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2009.02538.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:38:08Z","timestamp":1697258288000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2009.02538.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1537-2995.2009.02538.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02538.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,28]]}}}